Suchergebnisse - "Usmani, Saad Z"

PubPharm (308)

81

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Costa, L. | Lin, Y. | Cornell, R. | +22

82

BCMA-Targeted Biologic Therapies : The Next Standard of Care in Multiple Myeloma Therapy

enthalten in: Drugs | 2022

von Paul, B. | Rodriguez, C. | Usmani, S.

83

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA

enthalten in: Leukemia | 2022

von Facon, T. | Cook, G. | Usmani, S. | +25

84

BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy

enthalten in: Drugs | 2022

von Paul, B. | Rodriguez, C. | Usmani, S.

85

BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy

enthalten in: Drugs | 2022

von Paul, B. | Rodriguez, C. | Usmani, S.

86

BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy

enthalten in: Drugs | 2022

von Paul, B. | Rodriguez, C. | Usmani, S.

87

Extramedullary disease in multiple myeloma : a systematic literature review

enthalten in: Blood cancer journal | 2022

von Bladé, J. | Beksac, M. | Caers, J. | +8

88

Treatment outcomes of triple class refractory multiple myeloma : a benchmark for new therapies

enthalten in: Leukemia | 2022

von Bal, S. | Malek, E. | Kansagra, A. | +13

89

Post-protocol therapy and informative censoring in the CANDOR study - Authors' reply

enthalten in: The Lancet. Oncology | 2022

von Usmani, S. | Li, C. | Obreja, M. | +1

CommentOn: Lancet Oncol. 2022 Jan;23(1):65-76. - PMID 34871550

90

A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients

enthalten in: Bone marrow transplantation | 2022

von Tan, C. | Estrada-Merly, N. | Landau, H. | +17